1. Home
  2. TACO vs DBVT Comparison

TACO vs DBVT Comparison

Compare TACO & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TACO
  • DBVT
  • Stock Information
  • Founded
  • TACO 2024
  • DBVT 2002
  • Country
  • TACO United States
  • DBVT France
  • Employees
  • TACO N/A
  • DBVT N/A
  • Industry
  • TACO Blank Checks
  • DBVT Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TACO Finance
  • DBVT Health Care
  • Exchange
  • TACO Nasdaq
  • DBVT Nasdaq
  • Market Cap
  • TACO 393.9M
  • DBVT 464.0M
  • IPO Year
  • TACO 2025
  • DBVT N/A
  • Fundamental
  • Price
  • TACO $10.19
  • DBVT $13.57
  • Analyst Decision
  • TACO
  • DBVT Buy
  • Analyst Count
  • TACO 0
  • DBVT 5
  • Target Price
  • TACO N/A
  • DBVT $15.85
  • AVG Volume (30 Days)
  • TACO 496.5K
  • DBVT 122.3K
  • Earning Date
  • TACO 01-01-0001
  • DBVT 10-28-2025
  • Dividend Yield
  • TACO N/A
  • DBVT N/A
  • EPS Growth
  • TACO N/A
  • DBVT N/A
  • EPS
  • TACO N/A
  • DBVT N/A
  • Revenue
  • TACO N/A
  • DBVT $5,502,000.00
  • Revenue This Year
  • TACO N/A
  • DBVT $1,743.46
  • Revenue Next Year
  • TACO N/A
  • DBVT $1,045.66
  • P/E Ratio
  • TACO N/A
  • DBVT N/A
  • Revenue Growth
  • TACO N/A
  • DBVT N/A
  • 52 Week Low
  • TACO $10.16
  • DBVT $2.21
  • 52 Week High
  • TACO $11.32
  • DBVT $18.00
  • Technical
  • Relative Strength Index (RSI)
  • TACO N/A
  • DBVT 44.71
  • Support Level
  • TACO N/A
  • DBVT $12.56
  • Resistance Level
  • TACO N/A
  • DBVT $14.71
  • Average True Range (ATR)
  • TACO 0.00
  • DBVT 1.18
  • MACD
  • TACO 0.00
  • DBVT -0.32
  • Stochastic Oscillator
  • TACO 0.00
  • DBVT 19.30

About TACO Berto Acquisition Corp. Ordinary Shares

Berto Acquisition Corp is a blank check company.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: